Titre:
  • Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial
Auteur:Perez, Edith A; Yardley, Denise; Potter, David D.A.; Mailliez, Audrey; Moreno-Aspitia, Alvaro; Ahn, Jin Seok; Zhao, Carol; Hoch, Ute; Tagliaferri, Mary; Hannah, Alison L; Cortes, Javier; Awada, Ahmad; O'Shaughnessy, Joyce; Rugo, Hope; Twelves, Chris; Im, Seock Ah; Gómez-Pardo, Patricia; Schwartzberg, Lee L.S.; Diéras, Véronique
Informations sur la publication:Lancet oncology, 16, 15, page (1556-1568)
Statut de publication:Publié, 2015
Sujet CREF:Cancérologie
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(15)00332-0
info:pii/S1470204515003320
info:scp/84960964225
info:pmid/26482278